<DOC>
	<DOCNO>NCT01648140</DOCNO>
	<brief_summary>GSK2336805 novel hepatitis C virus ( HCV ) non-structural 5A ( NS5A ) inhibitor develop treatment chronic HCV infection . This Phase II , multicenter , parallel-group , randomize , dose-ranging study ass safety tolerability , antiviral activity , pharmacokinetics GSK2336805 2 dose level ( 40 60 mg ) combination pegylated interferon alfa-2a ( PEG ) ribavirin ( RIBA ) approximately 100 treatment-naïve subject chronic genotype 1 HCV infection . In separate nonrandomized single-arm cohort , 15 treatment-naïve subject genotype 4 chronic HCV infection enrol parallel dose level 60 mg GSK2336805 .</brief_summary>
	<brief_title>Dose Ranging GSK2336805 Combination Therapy</brief_title>
	<detailed_description>Subjects chronic genotype 1 hepatitis C virus ( HCV ) infection randomly assign 2:2:1 basis 1 3 treatment arm : T40 ( GSK2336805 40 mg PEG + RIBA ) T60 ( GSK2336805 60 mg PEG + RIBA ) PEG + RIBA telaprevir ( PRT ) . Randomization stratify interleukin 28B ( IL28B ) rs12979860 status ( C/C versus carriage T allele ) , HCV genotype ( 1a vs. 1b ) , plasma HCV Ribonucleic Acid ( RNA ) ( &lt; 800,000 IU/mL versus ≥800,000 IU/mL ) . An additional nonrandomized single-arm cohort subject chronic genotype 4 HCV infection enrol parallel . A maximum 15 genotype 4 subject receive GSK2336805 60 mg PEG + RIBA . The purpose cohort characterize antiviral activity GSK2336805 subject chronic genotype 4 HCV infection . The schedule assessment genotype 4 subject genotype 1 subject . Recruitment genotype 4 subject may terminate target sample genotype 1 subject randomize . Subjects GSK2336805 treatment arm achieve extend rapid virologic response ( eRVR ) receive total 24 week therapy ( 12 week GSK2336805 combination PEG + RIBA follow 12 week PEG + RIBA ) . Subjects HCV detectable Week 4 undetectable Week 12 receive total 48 week therapy ( 12 week GSK2336805 combination PEG + RIBA follow 36 week PEG + RIBA ) . Subjects telaprevir treatment control arm manage accord current product label treatment-naïve subject . Subjects complete treatment undergo follow-up monitoring 24 week completion therapy . At end 24-week follow-up visit , subject complete participation study . The total duration study 48 week subject achieve eRVR Week 12 72 week subject achieve eRVR Week 12 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Capable give write informed consent , include compliance requirement restriction list consent form . Male female age 18 70 year age , inclusive , Screening . Genotype 1 genotype 4 hepatitis C virus ( HCV ) infection assess Versant HCV Genotype assay 2.0 ( LiPA ) . Chronic HCV infection document least 1 measurement serum HCV RNA great equal 100,000 IU/mL measure Screening COBAS High Pure/COBAS TaqMan HCV Test v2.0 least one following : A positive antiHCV antibody , HCV RNA , HCV genotype test least 6 month prior Baseline ( Day 1 ) together positive HCV RNA antiHCV antibody test time Screening ; A positive HCV RNA test antiHCV antibody test time Screening together either liver biopsy consistent chronic HCV infection ( liver biopsy perform enrollment evidence chronic hepatitis C disease , presence fibrosis ) . Naïve HCV antiviral treatment ( ) , include , limited , immunomodulatory nucleoside/nucleotide treatment chronic HCV infection . Agree interleukin 28B ( IL28B ) genotyping . A subject , , opinion investigator , appropriate candidate pegylated interferon alpha2a ( PEG ) /ribavirin ( RIBA ) /protease inhibitor combination therapy genotype 1 subject PEG/RIBA combination therapy genotype 4 subject . Body mass index &gt; 18 kg/m2 exceed 36 kg/m2 . A liver biopsy obtain within 3 year ( 36 calendar month ) prior Day 1 visit , fibrosis classification noncirrhotic judge local pathologist ( define Knodell less equal 3 , Metavir le equal 2 , Ishak le equal 4 , Batts Ludwig less equal 2 ) . Both incomplete transition cirrhosis ( e.g. , Metavir score 3 ) consider cirrhosis . If recent ( &lt; 36 month ) liver biopsy available , studyqualifying biopsy must perform prior Baseline ( Day 1 ) . All fertile male female must use 2 form effective contraception treatment 24 week treatment end . Females , eligible enter participate study nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female hysterectomy bilateral oophorectomy ( ovariectomy ) bilateral tubal ligation postmenopausal ( demonstrate total cessation menses great 1 year ) . Females , eligible enter participate study childbearing potential negative urine serum pregnancy test Screening within 24hour period prior first dose study medication completely abstain intercourse 2 week exposure study medication , throughout clinical study , 24 week completion premature discontinuation study use 2 follow acceptable method contraception throughout clinical study 24 week completion premature discontinuation study : Any intrauterine device document failure rate &lt; 1 % per year Doublebarrier contraception ( condom , diaphragm , cervical cap use spermicidal jelly ) Male partner sterile prior female subject 's study entry sole sexual partner female Any contraceptive method document failure rate &lt; 1 % per year Otherwise healthy determine medical history , physical examination , ECG finding , clinical laboratory measurement perform Screening . Positive test Screening visit hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody History clinically significant chronic liver disease ( e.g. , hemochromatosis , autoimmune hepatitis , Wilson 's disease , 1antitrypsin deficiency , alcoholic liver disease , &gt; Grade 1 nonalcoholic steatohepatitis , toxin exposure ) . Subjects Gilbert 's syndrome otherwise meet inclusion/exclusion criterion eligible . History ascites , variceal hemorrhage , hepatic encephalopathy , condition consistent decompensated liver disease Positive result urine screen drug abuse test Screening ( unless use medical treatment , e.g. , prescription ) History alcohol/drug abuse dependence within 6 month study start ( unless participate controlled rehabilitation program ) Screening visit electrocardiogram correct QT ( QTc ) interval value &gt; 450 m and/or clinically significant electrocardiogram finding Personal family history Torsade de Pointes finding Pregnant nurse Male female partner pregnant Abnormal hematological biochemical parameter , include : Neutrophil count &lt; 1500 cells/mm3 ( &lt; 1250 cells/mm3 African American/Black subject ) Hemoglobin &lt; 11 g/dL female &lt; 12 g/dL male Creatinine great equal 1.5 × upper limit normal ( ULN ) Estimated creatinine clearance less equal 50 mL/min ( calculate use CockcroftGault formula ) Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase great equal 5 × ULN Total bilirubin great equal 2.0 × ULN ( except subject Gilbert 's syndrome ) Albumin le equal 3.0 g/dL Platelet count less equal 90,000/mm3 History major organ transplantation exist functional graft Thyroid dysfunction adequately control History suicide attempt hospitalization depression past 5 year History current ( within 6 month ) severe poorly control psychiatric disorder Subjects severe poorly control psychiatric disorder 6 month ago less 5 year ago eligible study participation must assess followed ( recommend ) mental health professional . History current evidence immunologic disorder ; cardiac pulmonary disease ; seizure disorder ; cancer history malignancy opinion investigator make subject unsuitable study . Treated herbal natural remedy antiviral activity within 30 day baseline visit history receive systemic antineoplastic immunomodulatory treatment ( include mycophenolate mofetil , thymosin alpha , supraphysiologic dos steroid &gt; 10 mg/day radiation ) within 6 month baseline visit expect treatment need time study . Participated clinical study investigational drug , biologic , device within 3 month prior first dose administration . History know allergy antiviral medication , include telaprevir , pegylated interferon alpha2a ( PEG ) , ribavirin ( RIBA ) , excipient investigational product history drug allergy , opinion investigator , contradict participation . Requires prohibit medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Genotype 4</keyword>
	<keyword>GSK2336805</keyword>
	<keyword>pegylated interferon</keyword>
	<keyword>telaprevir</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>chronic hepatitis C</keyword>
	<keyword>ribavirin</keyword>
	<keyword>NS5A inhibitor</keyword>
	<keyword>hepatitis C virus ( HCV ) infection</keyword>
</DOC>